LIM-domain-only 4 (LMO4) enhances CD8 + T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling.

Autor: Schelker RC; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. roland.schelker@ukr.de.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. roland.schelker@ukr.de.; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. roland.schelker@ukr.de.; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany. roland.schelker@ukr.de., Fioravanti J; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mastrogiovanni F; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Baldwin JG; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Rana N; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Li P; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Chen P; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Vadász T; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Spolski R; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Heuser-Loy C; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Slavkovic-Lukic D; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Noronha P; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Damiano G; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Raccosta L; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy., Maggioni D; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy., Pullugula S; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Lin JX; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Oh J; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Grandinetti P; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lecce M; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Hesse L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; University of Regensburg, Regensburg, Germany., Kocks E; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.; University of Regensburg, Regensburg, Germany., Martín-Santos A; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Gebhard C; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Telford WG; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ji Y; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Restifo NP; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Russo V; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Rehli M; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Herr W; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.; National Center for Tumor Diseases, WERA Site, Würzburg-Erlangen-Regensburg-Augsburg, Germany.; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany., Leonard WJ; Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. leonardw@nhlbi.nih.gov., Gattinoni L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. luca.gattinoni@lit.eu.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. luca.gattinoni@lit.eu.; University of Regensburg, Regensburg, Germany. luca.gattinoni@lit.eu.; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany. luca.gattinoni@lit.eu.
Jazyk: angličtina
Zdroj: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Aug 09; Vol. 9 (1), pp. 199. Date of Electronic Publication: 2024 Aug 09.
DOI: 10.1038/s41392-024-01915-z
Abstrakt: High frequencies of stem-like memory T cells in infusion products correlate with superior patient outcomes across multiple T cell therapy trials. Herein, we analyzed a published CRISPR activation screening to identify transcriptional regulators that could be harnessed to augment stem-like behavior in CD8 + T cells. Using IFN-γ production as a proxy for CD8 + T cell terminal differentiation, LMO4 emerged among the top hits inhibiting the development of effectors cells. Consistently, we found that Lmo4 was downregulated upon CD8 + T cell activation but maintained under culture conditions facilitating the formation of stem-like T cells. By employing a synthetic biology approach to ectopically express LMO4 in antitumor CD8 + T cells, we enabled selective expansion and enhanced persistence of transduced cells, while limiting their terminal differentiation and senescence. LMO4 overexpression promoted transcriptional programs regulating stemness, increasing the numbers of stem-like CD8 + memory T cells and enhancing their polyfunctionality and recall capacity. When tested in syngeneic and xenograft tumor models, LMO4 overexpression boosted CD8 + T cell antitumor immunity, resulting in enhanced tumor regression. Rather than directly modulating gene transcription, LMO4 bound to JAK1 and potentiated STAT3 signaling in response to IL-21, inducing the expression of target genes (Tcf7, Socs3, Junb, and Zfp36) crucial for memory responses. CRISPR/Cas9-deletion of Stat3 nullified the enhanced memory signature conferred by LMO4, thereby abrogating the therapeutic benefit of LMO4 overexpression. These results establish LMO4 overexpression as an effective strategy to boost CD8 + T cell stemness, providing a new synthetic biology tool to bolster the efficacy of T cell-based immunotherapies.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: